Hypoxia Inducible Factor 1 Alpha Market Share, Size,
This presentation is the property of its rightful owner.
Sponsored Links
1 / 4

Hypoxia Inducible Factor 1 Alpha Market Share, Size, Definition, Treatment,... PowerPoint PPT Presentation


Global Markets Direct's, 'Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H2 2016', provides in depth analysis on Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted pipeline therapeutics.

Download Presentation

Hypoxia Inducible Factor 1 Alpha Market Share, Size, Definit...

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Hypoxia inducible factor 1 alpha market share size definition treatment causes pipeline review h2 2016

Hypoxia Inducible Factor 1 Alpha Market Share, Size,

Definition, Treatment, Symptoms, Causes, Pipeline Review, H2

2016

Summary

Global Markets Direct's, 'Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS

Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing

Protein 8 or HIF1A) - Pipeline Review, H2 2016', provides in depth analysis on Hypoxia Inducible Factor 1 Alpha

(ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78

or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein

or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein

1 or PAS Domain Containing Protein 8 or HIF1A) , targeted therapeutics, complete with analysis by indications,

stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report

also covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases. Additionally, the report provides an overview of key players involved in

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

targeted therapeutics development and features dormant and discontinued projects.

Browse Full Report with TOC @ http://www.radiantinsights.com/research/hypoxia-inducible-factor-1-alpha-

arnt-interacting-protein

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and

nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's

proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that

all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes

ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision

making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope


Hypoxia inducible factor 1 alpha market share size definition treatment causes pipeline review h2 2016

- The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT

Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or

Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

- The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS

Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing

Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes

based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till

discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description,

descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic

Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS

Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects

- The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS

Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing

Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and

molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or

Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1

or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain

competitive advantage

- Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT

Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or

Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT

Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or

Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most

attractive projects to enhance and expand business potential and scope

Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/hypoxia-inducible-factor-1-

alpha-arnt-interacting-protein/request-sample

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

Overview 9

Therapeutics Development 10


Hypoxia inducible factor 1 alpha market share size definition treatment causes pipeline review h2 2016

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Products under Development by Stage of Development 10

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Products under Development by Therapy Area 11

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Products under Development by Indication 12

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Products under Development by Companies 16

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Products under Development by Universities/Institutes 19

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Therapeutics Assessment 21

Assessment by Monotherapy/Combination Products 21

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) -

Companies Involved in Therapeutics Development 28

Aileron Therapeutics, Inc. 28

CASI Pharmaceuticals Inc. 29

Cerulean Pharma, Inc. 30

Daiichi Sankyo Company, Limited 31

F. Hoffmann-La Roche Ltd. 32

InterMed Discovery GmbH 33

OncoImmune, Inc. 34

Peloton Therapeutics, Inc. 35

RXi Pharmaceuticals Corporation 36

Sorrento Therapeutics, Inc. 37

Transcriptogen Ltd 38

Vascular Biogenics Ltd. 39

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E

Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug

Profiles 40

A-503451A - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Browse Full Report with TOC @ http://www.radiantinsights.com/research/hypoxia-inducible-factor-1-alpha-

arnt-interacting-protein


Hypoxia inducible factor 1 alpha market share size definition treatment causes pipeline review h2 2016

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence

requirements. We assist and facilitate organizations and individuals procure market research reports, helping them

in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries

and a host of micro markets. In addition to over extensive database of reports, our experienced research

coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research

solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street,

Suite 3036 San Francisco,

CA 94105 United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Website: http://www.radiantinsights.com/

Email: [email protected]

Visit our Blog: http://chemicalsandmaterialsri.blogspot.com


  • Login